Phase II trials using time-to-event endpoints

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 143-154

  Tangen, Catherine M ^a   Crowley, John J ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123814970     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (21)

1. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, and Williamson SK. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. One. 10:1245-1251, 1992.
2. Mantel N and Byar DP. Evaluation of response-time data involving transient states: an illustration using heart transplant data. JASA 69:81-86, 1974.
3. Anderson JR, Cain KC, and Gelber RD. Analysis of survival by tumor response. J. Clin. One. 1(11):710-719, 1983.
4. Durie BGM, Jacobson J, Barlogie B, and Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J. Clin. One. 22:1857-1863, 2004.
5. McHugh K and Kao S. Response evaluation criteria in solid tumors (RECIST): problems and need for modifications in paediatric oncology? Brit. J. Radiol. 76(907):433-436, 2003.
6. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, and Munden RF. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma of the lung lesions: implications for assessment of tumor response. J. Clin. Onc. 21(13):2574-2582, 2003.
7. Kimura M and Tominaga T. Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. Breast Cancer 9(2):153-159, 2002.
8. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, and Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 43(1):71-74, 2004.
9. Folkman J. Fighting cancer by attacking its blood supply. Sci. Am. 1996;275:150-154.
10. Markham M. Challenges associated with evaluating the clinical utility of noncytotoxic pharmaceutical agents in oncology. J. Cancer Res. Clin. Oncol. 1997;123:581-582.
11. Fleming, TR. One sample multiple testing procedures for phase II clinical trials. Biometrics 38:143-151, 1982.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin. Trials 10:1-10, 1989.
13. Herndon, JE. A design alternative for two-stage phase II, multicenter cancer clinical trials. Controlled Clin. Trials 19:440-450, 1998.
14. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, and Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 19(1):265-272, 2001.
15. Mick R, Crowley JJ, and Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Controlled Clin. Trials 21:343-359, 2000.
16. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs. Clin. Cancer Res. 4:1079-1086, 1998.
17. Kalbfleisch JD and Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc., 1980.
18. Liu PY, LeBlanc M, and Desai M. False positive rates of randomized phase II designs. Controlled Clin. Trials 20:343-352, 1999.
19. Rosner GL, Stadler W, and Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. JCO 20(22):4478-4484, 2002.
20. Kopec JA, Abrahamowicz M, and Esdaile JM. Randomized discontinuation trials: utility and efficacy. J. Clin. Epidemiol. 46(9):959-971, 1993.
21. Friedman LM, Furberg, CD, and DeMets DL. Fundamentals of Clinical Trials. 2nd ed. Littleton, MA: PSG Publishing Company, 1985.